Valvular Heart DiseaseNCT04833283
The Effects of Intermittent Hypoxic-hyperoxic Preconditioning for Patients Undergoing Cardiopulmonary Bypass.
A study testing ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT) and ReOxy Cardio device in people with Valvular Heart Disease and Aortic Arch Aneurysm, run by I.M. Sechenov First Moscow State Medical University at 1 site in Russia.
Trial summary
The aim of the study is to evaluate the effects of intermittent hypoxic-hyperoxic training (IHHT) to protect myocardium against perioperative myocardial injury during cardiac surgery using cardiopulmonary bypass. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Valvular Heart Disease, Aortic Arch Aneurysm, Surgery
- What is being tested?
- ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT) and ReOxy Cardio device
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 115 participants
- Where
- 1 siteRussia
- Study dates
- 25 Jan 2021to 1 Dec 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Written consent to participate in the study 2. Male or female patients over 18 years 3. Indications for planned replacement of the aortic or mitral valves or operations on the aortic arch.
Who cannot join
- 1. Individual intolerance to the intermittent hypoxic-hyperoxic training
- 2. Acute coronary syndrome after hospitalization and before the surgery
- 3. The presence of an acute infectious process after hospitalization and before the surgery (fever, leukocytosis with a shift leukocyte formula to the left, increased erythrocyte sedimentation rate (ESR), increased C-reactive protein)
- 4. Uncompensated hypertension at the time of the procedure (systolic blood pres-sure more than 160 mm Hg, diastolic blood pressure more than 110 mm Hg)
- 5. Loss of consciousness, severe dizziness
- Non-inclusion criteria:
Show all 16Show fewer
- Occlusive atherosclerotic disease of lower limbs,
- Acute coronary syndrome within 4 weeks before entry
- Preoperative renal insufficiency (serum creatinine higher than 200 mmol/L),
- Acute infectious diseases
- Partial and secondary generalized forms of epilepsy,
- Uncompensated hypertension (Blood pressure at the time of the procedure: systolic blood pressure more than 160 mm Hg, diastolic blood pressure more than 110 mm Hg)
- Severe bronchial asthma with the development of respiratory failure of the II-III degree and individual intolerance to oxygen deficiency.
- 9. Severe hepatic impairment (class C child-Pugh) Intervention type
- 10. Mental illness (if patients are not capable of understanding the nature, significance and implications of the clinical trial)
- 11. Myocardial insufficiency as a component of multiple organ failure in decompensation of liver and kidney diseases
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effects of Intermittent Hypoxic-hyperoxic Preconditioning for Patients Undergoing Cardiac Surgery Using Cardiopulmonary Bypass and Its Impact on Postoperative Complications.
The aim of the study is to evaluate the effects of intermittent
hypoxic-hyperoxic training (IHHT) to protect myocardium against perioperative
myocardial injury during cardiac surgery using cardiopulmonary bypass.
Read the detailed description
This is a prospective, single-center, randomized controlled clinical trial, which will involve patients over 18 years old who would be recruited consecutively during pre-admission consultation at the I.M Sechenov First Moscow State Medical University Cardiac Surgery Department. All patients with a diagnosis of valvular heart disease, or aortic arch disease and indications for cardiac surgery, according to the European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines.
Five days before the operation, patients will be randomly assigned into two groups using a computer-generated randomization table: intermittent hypoxic-hyperoxic training and an intermittent hypoxic-hyperoxic training control group. For both groups laboratory testing (specific biomarkers - C-reactive protein, troponin I, fatty acid-binding protein (FABPs) and lactate) will be performed before training and after the surgery, and the hypoxic-inducible factor (HIF 1 alpha) would be implemented before and after the trainings.
Patients in the intermittent hypoxic-hyperoxic training group will undergo four daily procedures of interval hypoxic-hyperoxic training before cardiac surgery, using a normobaric device to obtain hypoxic and hyperoxic gas mixtures (ReOxy Cardio; Aimediq S.A., Luxemburg, Registration certificate in RU P3H 2014/1486). Before the start of the training, each patient would undergo a hypoxic test to assess the individual response to hypoxia, and to determine the rate of reduction of blood oxygen saturation (SpO2) with a finger pulse oximeter (Masimo SET, measurement accuracy ±2%). During 5 minutes the patient will receive air with reduced oxygen content (12%), through a mask under constant monitoring of the heart rate (HR) and SpO2. As a safety measure, minimal SpO2 would be set at 82% and maximal accepted increase of heart rate would be set to +50% of the initial heart rate. When these values would be reached, the supply of oxygen automatically would be switched to a hyperoxic gas mixture (35%-40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 was lower before the procedure), therefore depending on the rate of saturation reduction, will be taken 1 to 3 minutes (mean 1 min and 50 seconds). The intention is to create hyperoxic arterial oxygen tension and not to simply reduce the time required to recover from hypoxia. Intermittent hypoxic hyperoxic training would be considered successful if there were no significant side effects during the procedure such as angina pain, loss of consciousness, severe dizziness or other variants of significant subjective deterioration of the patient's condition. In the case of successfully passing the test, patients will proceed to the basic intermittent hypoxic hyperemic training. During the training, the hypoxic gas mixture will be given to the patient again in intermittent mode, based on the individual test parameters and alternating with the supply of a hyperoxic gas mixture. One cycle of the procedure consists of hypoxic and hyperoxygenated intervals, the duration of which will be regulated automatically according to the biofeedback principle, based on monitoring of individual values of SpO2 and heart rate. The duration of the hypoxic period ranges from 3 to 5 minutes, and the duration of the hyperoxic period ranges from 1 to 3 minutes, depending on the SpO2 recovery rate. The total time of the hypoxic gas mixture inhaled during one procedure will be 20-30 min. A final training would be conducted in the evening before the surgery. Patients in the intermittent hypoxic-hyperoxic training - control group also will undergo four daily procedures before surgery, using 40 min training periods with simulation of intermittent hypoxic-hyperoxic training by using the same equipment, the patient receives moistened air through a placebo mask under constant monitoring of heart rate and SpO2. Only the person who will conduct the training would know about the patient's allocation to a particular intervention group, the anesthesiologists and cardiac surgeons will not have access to this information. Episodes of cardiac arrhythmias, hypotension with a need for inotropic drug prescription, changes in electrocardiogram, pulse values and blood pressure levels will be recorded during surgery and the postoperative period.
Patients will be monitored for 7 days in the hospital, and 30 days after discharge to evaluate the complications.
Differences between groups will be assessed using the unpaired Student's t-test or the one-tailed Anova test followed by the Bonferroni post-test. Baseline corrected logistic regression models will be used to estimate the training effect in relation to primary and secondary endpoints. Statistical significance will be set at 0.05 to test hypotheses.
- Conditions
- Valvular Heart Disease, Aortic Arch Aneurysm, Surgery
- Being tested
- ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT), ReOxy Cardio device
- Keywords
- cardiac pulmonary bypass, reperfusion, interval hypoxic-hyperoxic training, preconditioning, valvular heart disease, aortic arch aneurysm
- Medical subject headings
- Heart Valve Diseases, Aneurysm, Aortic Arch
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)Device
Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s).
ReOxy Cardio deviceDevice
Perform 4 trainings daily of intermittent hypoxic-hyperoxic trainings before surgery, using 40 min trainings periods, whereas moistened air will be delivered through a mask under constant monitoring of heart rate (HR) and SpO2.
| Study group | Role | What they receive |
|---|---|---|
| the intervention group intermittent hypoxic-hyperoxic training | Experimental | the intervention group is patients performing intermittent hypoxic-hyperoxic training before operation. ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)
Intervention Description: Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s). Receives: Device: ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT) |
| the control group | Placebo comparator | intermittent hypoxic-hyperoxic training control group will be identical to the main group, also underwent four daily procedures before surgery using 40 min training periods with simulation of intermittent hypoxic-hyperoxic trainings by using the same equipment, whereas moistened air will be delivered through a placebo mask Receives: Device: ReOxy Cardio device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Death from a cardiac cause
Death from cardiac causes during the current hospitalization or 30 days after discharge
Measured: The first 30 days from the date of discharge
Myocardial infarction
Myocardial infarction after current surgery and one month after discharge
Measured: through study completion, an average of 1 month after discharge
Stroke
Stroke in postoperative period until the date of the discharge
Measured: through study completion, an average of 1 month after discharge
Secondary outcomes (7)
Electrocardiogram deterioration caused by myocardial ischemia;
Electrocardiogram deterioration caused by myocardial ischemia (ST segment elevation or depression, Q wave, negative T wave ) during hospitalization or 30 days after discharge
Measured: through study completion, an average of 1 month after discharge
Angina pectoris - typical chest pain III - IV functional class (Canadian Cardiovascular Society classification)
Having an angina pectoris during hospitalization or 30 days after discharge
Measured: through study completion, an average of 1 month after discharge
Documented episodes of atrial fibrillation/ atrial flutter.
Documented episodes of atrial fibrillation or atrial flutter during hospitalization or 30 days after discharge
Measured: through study completion, an average of 1 month after discharge
Ventricular proarrhythmia requiring additional therapy
Detection of ventricular proarrhythmia during hospitalization or 30 days after discharge
Measured: through study completion, an average of 1 month after discharge
Atrioventricular block 2-3 degrees
Atrioventricular block 2-3 degree during hospitalization or 30 days after discharge
Measured: through study completion, an average of 1 month after discharge
Episodes of hypotension requiring additional therapy
Episodes of hypotension (systolic blood pressure of less than 90 mmHg/ diastolic of less than 60 mmHg) requiring additional therapy during hospitalization or 30 days after discharge
Measured: through study completion, an average of 1 month after discharge
Length of stay in the intensive care unit
Measured: through study completion, an average of 1month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2021
- Study start25 Jan 2021
- Primary completion15 May 2022
- Study completion1 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Valvular Heart DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 115 participants (actual)
Sponsor and investigators
- Lead sponsor
- I.M. Sechenov First Moscow State Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04833283
- Sponsor's protocol ID
- 101499310010796
- Status last verified
- May 2022
- First submitted
- 23 Mar 2021
- Last updated
- 7 Dec 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data disclosure is not permitted by the local ethics committee. For more information about the study, you need to contact the principal investigator.
Study at a glance
From the registry record, last updated by the sponsor on 7 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Intermittent Hypoxic-hyperoxic Preconditioning for Patients Undergoing Cardiac Surgery Using Cardiopulmonary Bypass and Its Impact on Postoperative Complications.
- ClinicalTrials.gov ID
- NCT04833283
- Acronym / sponsor ID
- 101499310010796
- Conditions
- Valvular Heart Disease, Aortic Arch Aneurysm, Surgery
- Keywords
- cardiac pulmonary bypass, reperfusion, interval hypoxic-hyperoxic training, preconditioning, valvular heart disease, aortic arch aneurysm
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 115 participants (actual)
- Lead sponsor
- I.M. Sechenov First Moscow State Medical UniversityUniversity, hospital or other
- Study start
- 25 Jan 2021 (actual)
- Primary completion
- 15 May 2022 (actual)
- Study completion
- 1 Dec 2022 (actual)
- First posted
- 6 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to evaluate the effects of intermittent
hypoxic-hyperoxic training (IHHT) to protect myocardium against perioperative
myocardial injury during cardiac surgery using cardiopulmonary bypass.
Detailed description
This is a prospective, single-center, randomized controlled clinical trial, which will involve patients over 18 years old who would be recruited consecutively during pre-admission consultation at the I.M Sechenov First Moscow State Medical University Cardiac Surgery Department. All patients with a diagnosis of valvular heart disease, or aortic arch disease and indications for cardiac surgery, according to the European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines.
Five days before the operation, patients will be randomly assigned into two groups using a computer-generated randomization table: intermittent hypoxic-hyperoxic training and an intermittent hypoxic-hyperoxic training control group. For both groups laboratory testing (specific biomarkers - C-reactive protein, troponin I, fatty acid-binding protein (FABPs) and lactate) will be performed before training and after the surgery, and the hypoxic-inducible factor (HIF 1 alpha) would be implemented before and after the trainings.
Patients in the intermittent hypoxic-hyperoxic training group will undergo four daily procedures of interval hypoxic-hyperoxic training before cardiac surgery, using a normobaric device to obtain hypoxic and hyperoxic gas mixtures (ReOxy Cardio; Aimediq S.A., Luxemburg, Registration certificate in RU P3H 2014/1486). Before the start of the training, each patient would undergo a hypoxic test to assess the individual response to hypoxia, and to determine the rate of reduction of blood oxygen saturation (SpO2) with a finger pulse oximeter (Masimo SET, measurement accuracy ±2%). During 5 minutes the patient will receive air with reduced oxygen content (12%), through a mask under constant monitoring of the heart rate (HR) and SpO2. As a safety measure, minimal SpO2 would be set at 82% and maximal accepted increase of heart rate would be set to +50% of the initial heart rate. When these values would be reached, the supply of oxygen automatically would be switched to a hyperoxic gas mixture (35%-40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 was lower before the procedure), therefore depending on the rate of saturation reduction, will be taken 1 to 3 minutes (mean 1 min and 50 seconds). The intention is to create hyperoxic arterial oxygen tension and not to simply reduce the time required to recover from hypoxia. Intermittent hypoxic hyperoxic training would be considered successful if there were no significant side effects during the procedure such as angina pain, loss of consciousness, severe dizziness or other variants of significant subjective deterioration of the patient's condition. In the case of successfully passing the test, patients will proceed to the basic intermittent hypoxic hyperemic training. During the training, the hypoxic gas mixture will be given to the patient again in intermittent mode, based on the individual test parameters and alternating with the supply of a hyperoxic gas mixture. One cycle of the procedure consists of hypoxic and hyperoxygenated intervals, the duration of which will be regulated automatically according to the biofeedback principle, based on monitoring of individual values of SpO2 and heart rate. The duration of the hypoxic period ranges from 3 to 5 minutes, and the duration of the hyperoxic period ranges from 1 to 3 minutes, depending on the SpO2 recovery rate. The total time of the hypoxic gas mixture inhaled during one procedure will be 20-30 min. A final training would be conducted in the evening before the surgery. Patients in the intermittent hypoxic-hyperoxic training - control group also will undergo four daily procedures before surgery, using 40 min training periods with simulation of intermittent hypoxic-hyperoxic training by using the same equipment, the patient receives moistened air through a placebo mask under constant monitoring of heart rate and SpO2. Only the person who will conduct the training would know about the patient's allocation to a particular intervention group, the anesthesiologists and cardiac surgeons will not have access to this information. Episodes of cardiac arrhythmias, hypotension with a need for inotropic drug prescription, changes in electrocardiogram, pulse values and blood pressure levels will be recorded during surgery and the postoperative period.
Patients will be monitored for 7 days in the hospital, and 30 days after discharge to evaluate the complications.
Differences between groups will be assessed using the unpaired Student's t-test or the one-tailed Anova test followed by the Bonferroni post-test. Baseline corrected logistic regression models will be used to estimate the training effect in relation to primary and secondary endpoints. Statistical significance will be set at 0.05 to test hypotheses.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| the intervention group intermittent hypoxic-hyperoxic training | Experimental | Device: ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)the intervention group is patients performing intermittent hypoxic-hyperoxic training before operation. ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT) Intervention Description: Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s). |
| the control group | Placebo comparator | Device: ReOxy Cardio deviceintermittent hypoxic-hyperoxic training control group will be identical to the main group, also underwent four daily procedures before surgery using 40 min training periods with simulation of intermittent hypoxic-hyperoxic trainings by using the same equipment, whereas moistened air will be delivered through a placebo mask |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- 1. Written consent to participate in the study 2. Male or female patients over 18 years 3. Indications for planned replacement of the aortic or mitral valves or operations on the aortic arch.
Key exclusion criteria (16 listed)
- 1. Individual intolerance to the intermittent hypoxic-hyperoxic training
- 2. Acute coronary syndrome after hospitalization and before the surgery
- 3. The presence of an acute infectious process after hospitalization and before the surgery (fever, leukocytosis with a shift leukocyte formula to the left, increased erythrocyte sedimentation rate (ESR), increased C-reactive protein)
- 4. Uncompensated hypertension at the time of the procedure (systolic blood pres-sure more than 160 mm Hg, diastolic blood pressure more than 110 mm Hg)
- 5. Loss of consciousness, severe dizziness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s). | Device | the intervention group intermittent hypoxic-hyperoxic training |
| ReOxy Cardio devicePerform 4 trainings daily of intermittent hypoxic-hyperoxic trainings before surgery, using 40 min trainings periods, whereas moistened air will be delivered through a mask under constant monitoring of heart rate (HR) and SpO2. | Device | the control group |
Primary outcome
Death from a cardiac cause
Time frame: The first 30 days from the date of discharge
Death from cardiac causes during the current hospitalization or 30 days after discharge
Myocardial infarction
Time frame: through study completion, an average of 1 month after discharge
Myocardial infarction after current surgery and one month after discharge
Stroke
Time frame: through study completion, an average of 1 month after discharge
Stroke in postoperative period until the date of the discharge
7 secondary outcomes
Electrocardiogram deterioration caused by myocardial ischemia;
Time frame: through study completion, an average of 1 month after discharge
Angina pectoris - typical chest pain III - IV functional class (Canadian Cardiovascular Society classification)
Time frame: through study completion, an average of 1 month after discharge
Documented episodes of atrial fibrillation/ atrial flutter.
Time frame: through study completion, an average of 1 month after discharge
Ventricular proarrhythmia requiring additional therapy
Time frame: through study completion, an average of 1 month after discharge
Atrioventricular block 2-3 degrees
Time frame: through study completion, an average of 1 month after discharge
Episodes of hypotension requiring additional therapy
Time frame: through study completion, an average of 1 month after discharge
Length of stay in the intensive care unit
Time frame: through study completion, an average of 1month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Dec 2022.
- Individual participant dataSharing planned: No. Data disclosure is not permitted by the local ethics committee. For more information about the study, you need to contact the principal investigator.
Related trials for Valvular Heart Disease
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
RecruitingObservational study
A Post-Market Assessment of the Safety and Performance of the TriClip™ System
Tricuspid Regurgitation (TR)
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT) and ReOxy Cardio device in people with Valvular Heart Disease and Aortic Arch Aneurysm, run by I.M. Sechenov First Moscow State Medical University at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Death from a cardiac cause (time frame: The first 30 days from the date of discharge). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Dec 2022.